JP6122868B2 - 抗ウイルス剤としてのピラゾロ［１，５−ａ］ピリミジン - Google Patents

抗ウイルス剤としてのピラゾロ［１，５−ａ］ピリミジン Download PDF

Info

Publication number
JP6122868B2
JP6122868B2 JP2014548913A JP2014548913A JP6122868B2 JP 6122868 B2 JP6122868 B2 JP 6122868B2 JP 2014548913 A JP2014548913 A JP 2014548913A JP 2014548913 A JP2014548913 A JP 2014548913A JP 6122868 B2 JP6122868 B2 JP 6122868B2
Authority
JP
Japan
Prior art keywords
compound
formula
alkyl
pharmaceutically acceptable
nhr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014548913A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015506348A (ja
JP2015506348A5 (enExample
Inventor
コンスタンティン ジー． ブージャムラ，
コンスタンティン ジー． ブージャムラ，
ホン チャン フイ，
ホン チャン フイ，
ペートル ヤンサ，
ペートル ヤンサ，
リチャード エル． マックマン，
リチャード エル． マックマン，
ジェイ ピー． パリッシュ，
ジェイ ピー． パリッシュ，
マイケル サンギ，
マイケル サンギ，
ダスティン シーゲル，
ダスティン シーゲル，
デイビッド スペランディオ，
デイビッド スペランディオ，
ハイ ヤン，
ハイ ヤン，
Original Assignee
ギリアード サイエンシーズ， インコーポレイテッド
ギリアード サイエンシーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ギリアード サイエンシーズ， インコーポレイテッド, ギリアード サイエンシーズ， インコーポレイテッド filed Critical ギリアード サイエンシーズ， インコーポレイテッド
Publication of JP2015506348A publication Critical patent/JP2015506348A/ja
Publication of JP2015506348A5 publication Critical patent/JP2015506348A5/ja
Application granted granted Critical
Publication of JP6122868B2 publication Critical patent/JP6122868B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP2014548913A 2011-12-22 2012-12-20 抗ウイルス剤としてのピラゾロ［１，５−ａ］ピリミジン Active JP6122868B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161579625P 2011-12-22 2011-12-22
US61/579,625 2011-12-22
US201261618510P 2012-03-30 2012-03-30
US61/618,510 2012-03-30
PCT/US2012/071065 WO2013096681A1 (en) 2011-12-22 2012-12-20 Pyrazolo[1,5-a]pyrimidines as antiviral agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016224719A Division JP2017036336A (ja) 2011-12-22 2016-11-18 抗ウイルス剤としてのピラゾロ［１，５−ａ］ピリミジン

Publications (3)

Publication Number Publication Date
JP2015506348A JP2015506348A (ja) 2015-03-02
JP2015506348A5 JP2015506348A5 (enExample) 2016-02-12
JP6122868B2 true JP6122868B2 (ja) 2017-04-26

Family

ID=47557523

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014548913A Active JP6122868B2 (ja) 2011-12-22 2012-12-20 抗ウイルス剤としてのピラゾロ［１，５−ａ］ピリミジン
JP2016224719A Withdrawn JP2017036336A (ja) 2011-12-22 2016-11-18 抗ウイルス剤としてのピラゾロ［１，５−ａ］ピリミジン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016224719A Withdrawn JP2017036336A (ja) 2011-12-22 2016-11-18 抗ウイルス剤としてのピラゾロ［１，５−ａ］ピリミジン

Country Status (8)

Country Link
US (3) US8946238B2 (enExample)
EP (1) EP2794611B1 (enExample)
JP (2) JP6122868B2 (enExample)
AU (1) AU2012358805B2 (enExample)
CA (1) CA2858096C (enExample)
ES (1) ES2647486T3 (enExample)
PT (1) PT2794611T (enExample)
WO (1) WO2013096681A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5878171B2 (ja) 2010-06-24 2016-03-08 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス剤としてのピラゾロ［１，５−ａ］ピリミジン
EP2794611B1 (en) 2011-12-22 2017-10-11 Gilead Sciences, Inc. Pyrazolo[1,5-a]pyrimidines as antiviral agents
HRP20191754T1 (hr) 2012-04-17 2020-01-24 Gilead Sciences, Inc. Spojevi i postupci za antivirusno liječenje
NZ716822A (en) 2013-08-21 2017-10-27 Alios Biopharma Inc Antiviral compounds
SG11201700851WA (en) * 2014-08-05 2017-03-30 Alios Biopharma Inc Combination therapy for treating a paramyxovirus
CN107207512B (zh) * 2014-12-08 2019-09-10 爱尔兰詹森科学公司 对呼吸道合胞病毒(rsv)的复制具有抑制活性的哌啶取代的三环吡唑并[1，5-a]嘧啶衍生物
SG11201704397VA (en) * 2014-12-08 2017-06-29 Janssen Sciences Ireland Uc Piperidine substituted pyrazolo[1,5-a]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (rsv)
CN118286245A (zh) 2014-12-26 2024-07-05 埃莫里大学 N4-羟基胞苷和衍生物及与其相关的抗病毒用途
MA41614A (fr) 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
JP2018076234A (ja) * 2015-03-16 2018-05-17 大正製薬株式会社 ピラゾロ［１，５−ａ］ピリミジン化合物
CA2992839A1 (en) 2015-07-22 2017-01-26 Enanta Pharmaceuticals, Inc. Benzodiazepine derivatives as rsv inhibitors
EP3402799B1 (en) 2016-01-15 2022-05-04 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
EP4483875A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN109153682B (zh) * 2016-05-20 2021-05-25 豪夫迈·罗氏有限公司 用于治疗感染性疾病的具有氧、硫和氮连接基的新的吡嗪化合物
KR102592801B1 (ko) 2016-10-06 2023-10-20 오버스 쎄라퓨틱스, 인코포레이티드 에플로르니틴의 투여를 위한 제형
AU2018221820B2 (en) 2017-02-16 2023-11-02 Enanta Pharmaceuticals, Inc. Processes for the preparation of benzodiazepine derivatives
WO2018237026A1 (en) 2017-06-20 2018-12-27 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
WO2019006295A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
CN111108105B (zh) 2017-09-22 2023-03-31 朱比兰特埃皮帕德有限公司 作为pad抑制剂的杂环化合物
CA3077309A1 (en) 2017-09-29 2019-04-04 Enanta Pharmaceuticals, Inc. Combination pharmaceutical agents as rsv inhibitors
KR102782563B1 (ko) 2017-10-18 2025-03-14 주빌런트 에피파드 엘엘씨 Pad 억제제로서의 이미다조-피리딘 화합물
AU2018362046B2 (en) 2017-11-06 2023-04-13 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
JP7228588B2 (ja) 2017-11-13 2023-02-24 エナンタ ファーマシューティカルズ インコーポレイテッド ベンゾジアゼピン－２－オンおよびベンゾアゼピン－２－オン誘導体の分割方法
HUE067265T2 (hu) 2017-11-24 2024-10-28 Jubilant Episcribe Llc Heterociklusos vegyületek mint PRMT5 inhibitorok
RS66222B1 (sr) 2017-12-07 2024-12-31 Univ Emory N4-hidroksicitidin i derivati i antivirusne upotrebe povezane sa njim
EA202091835A1 (ru) 2018-01-31 2020-10-20 Янссен Сайенсиз Айрлэнд Анлимитед Компани Замещенные циклоалкилом пиразолопиримидины, обладающие активностью против rsv
EP3765453A1 (en) 2018-03-13 2021-01-20 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
KR20210005569A (ko) 2018-04-23 2021-01-14 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Rsv에 대한 활성을 갖는 헤테로방향족 화합물
MA54286A (fr) * 2018-11-26 2021-10-06 Janssen Sciences Ireland Unlimited Co Autres composés hétéroaromatiques ayant une activité contre le vrs
JPWO2020138015A1 (ja) 2018-12-27 2021-11-18 大正製薬株式会社 ピラゾロ［１，５−ａ］ピリミジン大環状化合物
AU2020240024B2 (en) 2019-03-18 2025-06-26 Enanta Pharmaceuticals, Inc Benzodiazepine derivatives as RSV inhibitors
TWI864048B (zh) 2019-10-04 2024-12-01 美商安塔製藥公司 抗病毒雜環化合物、其醫藥組成物及其用途
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
US11534439B2 (en) 2020-07-07 2022-12-27 Enanta Pharmaceuticals, Inc. Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors
US11945824B2 (en) 2020-10-19 2024-04-02 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
JP2024507561A (ja) 2021-02-26 2024-02-20 エナンタ ファーマシューティカルズ インコーポレイテッド 抗ウイルス複素環式化合物
CA3223875A1 (en) * 2021-06-25 2022-12-29 Shigeru Matsuoka Heterocycloalkyl-substituted polyheteroazole derivatives as medicaments for treating and/or preventing rs virus infections
AR129003A1 (es) 2022-04-07 2024-07-03 Enanta Pharm Inc Compuestos heterocíclicos antivirales
US12162857B2 (en) 2022-04-27 2024-12-10 Enanta Pharmaceuticals, Inc. Antiviral compounds
CN117658980A (zh) * 2022-09-08 2024-03-08 郑州同源康医药有限公司 双环类prmt5抑制剂
CN115710200B (zh) * 2022-11-21 2024-08-09 重庆医科大学 苯甲酰氟类化合物、苯甲酸类化合物及其制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543413A (en) * 1994-02-25 1996-08-06 Regents Of The University Of Michigan Heterocyclic thioamides and related analogs as antiviral agents with a unique mode of action
US6342501B1 (en) 1994-02-25 2002-01-29 The Regents Of The University Of Michigan Pyrrolo[2,3-d] pyrimidines as antiviral agents
BR9508178A (pt) 1994-06-29 1997-11-18 Smithkline Beecham Corp Antagonistas de receptor de vitronectina
KR20010041015A (ko) 1998-02-17 2001-05-15 윌리엄 제이. 리플린 항바이러스성 피리미딘 유도체
TWI225488B (en) 1999-12-21 2004-12-21 Janssen Pharmaceutica Nv Derivatives of homopiperidinyl substituted benzimidazole analogues
JP2005526090A (ja) 2002-03-13 2005-09-02 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 神経伝達物質調節因子としてのピラゾロ（１，５−ａ）ピリジン誘導体
WO2003095455A2 (en) * 2002-05-10 2003-11-20 Smithkline Beecham Corporation Substituted pyrazolopyrimidines
EP1511751B1 (en) * 2002-06-04 2008-03-19 Neogenesis Pharmaceuticals, Inc. Pyrazolo[1,5-a]pyrimidine compounds as antiviral agents
DE10247271A1 (de) 2002-10-10 2004-08-26 Grünenthal GmbH Substituierte C-Imidazo[1,2-a]pyridin-3-yle
JP5384793B2 (ja) 2003-12-24 2014-01-08 バイオウタ サイエンティフィック マネジメント プロプライエタリー リミテッド 呼吸器合胞体ウイルス感染の処置のための多環式薬剤
SG133452A1 (en) 2005-12-30 2007-07-30 Novartis Ag Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases
JP2010510245A (ja) 2006-11-21 2010-04-02 スミスクライン ビーチャム コーポレーション 抗ウイルス化合物
WO2009076679A2 (en) 2007-12-13 2009-06-18 Alnylam Pharmaceuticals Inc. Methods and compositions for prevention or treatment of rsv infection
EP2234486A4 (en) 2007-12-19 2011-09-14 Scripps Research Inst BENZIMIDAZOLES AND ANALOGS AS INHIBITORS OF RHO-KINASE
BRPI0908529A2 (pt) 2008-02-26 2015-09-29 Novartis Ag composto orgânicos
EP2271646A1 (en) * 2008-03-31 2011-01-12 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
CA2721060A1 (en) 2008-04-09 2009-10-15 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US20110275673A1 (en) 2008-09-19 2011-11-10 Yibin Xiang Inhibitors of sphingosine kinase 1
EP2182081B1 (de) 2008-10-29 2014-01-22 Neue Materialien Bayreuth GmbH Verfahren zur thermischen Behandlung eines beschichteten Stahlblechkörpers
PE20120124A1 (es) 2008-12-03 2012-03-17 Presidio Pharmaceuticals Inc Derivados 2-pirrolidin-3-il-1h-imidazol, como inhibidores de la proteina no estructural 5a del virus de la heptitis c
CA2746943A1 (en) 2008-12-18 2010-07-15 Boehringer Ingelheim International Gmbh Serotonin 5-ht2b receptor inhibitors
US8541424B2 (en) 2008-12-23 2013-09-24 Abbott Laboratories Anti-viral compounds
TWI438200B (zh) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
CA2753382C (en) 2009-02-27 2014-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8889674B2 (en) 2009-03-05 2014-11-18 Shionogi & Co., Ltd. Piperidine and pyrrolidine derivatives having NPY Y5 receptor antagonism
PL2368890T3 (pl) 2009-06-11 2013-10-31 Abbvie Bahamas Ltd Inhibitory wirusa zapalenia wątroby C
WO2010148006A1 (en) 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
RU2540897C2 (ru) 2009-08-07 2015-02-10 Тиботек Фармасьютикалз Производные бис-бензимидазола в качестве ингибиторов вируса гепатита с
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
SG10201408512RA (en) * 2009-12-23 2015-02-27 Univ Leuven Kath Novel antiviral compounds
WO2011099832A2 (en) 2010-02-12 2011-08-18 Crystalgenomics, Inc. Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
WO2011149856A1 (en) 2010-05-24 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
JP5878171B2 (ja) 2010-06-24 2016-03-08 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス剤としてのピラゾロ［１，５−ａ］ピリミジン
MA34470B1 (fr) 2010-07-22 2013-08-01 Gilead Sciences Inc Procédés et composés pour traiter des infections à virus paramyxoviridae
EP2794611B1 (en) 2011-12-22 2017-10-11 Gilead Sciences, Inc. Pyrazolo[1,5-a]pyrimidines as antiviral agents
HRP20191754T1 (hr) 2012-04-17 2020-01-24 Gilead Sciences, Inc. Spojevi i postupci za antivirusno liječenje

Also Published As

Publication number Publication date
WO2013096681A1 (en) 2013-06-27
JP2015506348A (ja) 2015-03-02
ES2647486T3 (es) 2017-12-21
AU2012358805A1 (en) 2014-06-19
AU2012358805A8 (en) 2014-06-26
NZ625737A (en) 2016-04-29
JP2017036336A (ja) 2017-02-16
AU2012358805B2 (en) 2017-07-20
US8946238B2 (en) 2015-02-03
US20130164280A1 (en) 2013-06-27
CA2858096C (en) 2020-06-23
EP2794611A1 (en) 2014-10-29
CA2858096A1 (en) 2013-06-27
US9278975B2 (en) 2016-03-08
EP2794611B1 (en) 2017-10-11
US20150166546A1 (en) 2015-06-18
PT2794611T (pt) 2017-12-06
US20160235748A1 (en) 2016-08-18

Similar Documents

Publication Publication Date Title
JP6122868B2 (ja) 抗ウイルス剤としてのピラゾロ［１，５−ａ］ピリミジン
US10174038B2 (en) Compounds and methods for antiviral treatment
JP5878171B2 (ja) 抗ウイルス剤としてのピラゾロ［１，５−ａ］ピリミジン
NZ625737B2 (en) Pyrazolo[1,5-a]pyrimidines as antiviral agents
HK1207076B (en) Compounds and methods for antiviral treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20160620

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160623

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170306

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170403

R150 Certificate of patent or registration of utility model

Ref document number: 6122868

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250